Thank you to our speakers, sponsors, and delegates who joined us in Boston for the summit! If you are interested in the 2026 event, please get in touch at info@hansonwade.com
Ran May 19-20, Boston MA
Accelerate partnership interest in your protein degradation pipeline or platform, by hearing first-hand:
What: What are pharma’s targets of interest, and what data is sparking or prohibiting deal-making across TPD?
Who: Who is the right person at each pharma, specifically for induced proximity assets?
How: How are pharma analyzing data for a research collaboration versus a licensing deal?
ATTENDING COMPANIES INCLUDED
WHY JOIN THE TPD & INDUCED PROXIMITY PHARMA PARTERING SUMMIT IN 2026?
In 2025, you improved your understanding of pharma’s targets of interest to refine your fit & differentiation within the market.
In association with the Beacon Clinical Trials Database and the longest-standing TPD Summit Series for scientific exchange, the TPD & Induced Proximity Pharma Partnering Summit united business heads to amplify collaborative success.
"There's so many phenomenal drugs that are coming along in the TPD space, it’s going to get interesting. There's been an influx of research and minds, and data is developing and looking compelling. Combined with the influx of cash, it's going to help it advance that much faster. I don't see it fizzling away like other things may have in past.“ Pharma BD&L Director
This was the most efficient event of your partnering conference calendar, where you spoke to dozens of relevant prospective partners face-to-face, saw how peers were pitching themselves in the market, and comprehensively experienced what pharma wanted to see, to ensure your slide deck lands.
Key Figures from Partnering Series
of the correct pharma contacts, all qualified to speak to and with time to discuss your company
total attendees, to minimize competition for pharma’s time and ensure a critical mass for competitive intelligence
C-level attendance from biotech to ensure high yielding conversations with other biotech decision-makers
acceptance rate of meetings versus 11% industry standard, to guarantee a greater efficiency of face-to-face meetings
Size of Networking Opportunity
Alignment with the Total Audience
Scientifically Relevant, Qualified Business Decision Makers
Intersecting scientific market insights with a targeted critical mass, increased efficiency and yield of networking opportunities. You maximized your opportunity to pitch and receive strategic direction from pharma, free from conflicting priorities larger conferences bring.
Protected Icebreaker Opportunities
Select Your Pharma, Sit at Their Table
To guarantee you got face-time and the opportunity to introduce yourself to the pharma that were the highest priority to you, you got to select your tables for the Pharma Icebreaker Roundtables and were allocated a time slot. You used this to meet pharma you hadn't secured a time with through the portal, or touched base for feedback on a lapsed conversation. You heard how others pitched themselves and evaluated early in the meeting if there was scope to follow up for a deeper discussion.
One-on-One Partnering Portal
Schedule Meetings in Advance, with the Industry’s Best Partnering Portal
You prepared and pre-arranged your most important meetings by reviewing the full attendee list, company profiles and reaching out to fill your meeting calendar in advance. You blocked out agenda sessions critical to attend and made yourself available to maximize meeting opportunities.
EXPERT SPEAKERS INCLUDED
Adam Gilbert
Executive Director, External Innovation Accelerator
Pfizer
Elena Diez
Senior Director External Innovation
JanssenÂ
Ann Rowley
Director - Targeted
Protein Degradation
Merck
Randolph Lopez
Chief Technology Officer & Co-Founder
A-Alpha Bio
Anna Rivkin
Chief Business Officer
 Foghorn Therapeutics
OTHER HANSON WADE SUMMITS
